Floatz logo

SATOREOTIDE TRIZOXETAN

Gastroenteropancreatic Neuroendocrine Tumors

Ipsenprotein_peptidePhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

34 Active assets in the Gastroenteropancreatic Neuroendocrine Tumors cohort.

Asset / SponsorPhaseRating
Oxodotreotide
National Cancer Institute (NCI)
Phase 4BBB
Octreotide Pamoate
Novartis Pharmaceuticals
Phase 3BB
Oxodotreotide
Vanderbilt-Ingram Cancer Center
Phase 4BB
EUDEMINE INJECTION
University of Maryland, Baltimore
Phase 4BB
Everolimus
RayzeBio, Inc.
Phase 3BB

View all 46 →

Same molecule, other indications

SATOREOTIDE TRIZOXETAN is also rated in:

Small Cell Lung Cancer and Breast CancerDormant
C
Indicative ·
39 / 100
View asset →
breast cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →